공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 세포 표면 마커 식별 시장

Cell Surface Markers

리서치사 Global Industry Analysts, Inc.
발행일 2021년 01월 상품 코드 346155
페이지 정보 영문 499 Pages
가격
US $ 5,450 ₩ 6,204,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 16,350 ₩ 18,612,000 PDF (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 세포 표면 마커 식별 시장 Cell Surface Markers
발행일 : 2021년 01월 페이지 정보 : 영문 499 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 세포 표면 마커 식별(Cell Surface Markers Identification) 시장에 대해 조사했으며, 시장 동향과 2020년까지 예측, 지역별 동향, 주요 진출 기업 개요 등의 정보를 전해드립니다.

제1장 서론, 조사 방법, 제품 정의

제2장 주요 요약

  • 업계 개요
    • 서론
    • 실험실 자동화에 대한 주력이 기회로
    • 시장 전망
    • 선진국 : 주요 매출 기여 지역
    • 개발도상국 : 향후 성장 핫스팟
    • 과거의 불황과 그것이 의료 및 연구 장비 시장에 미치는 영향
    • 안정된 지출 전망이 시장 성장의 기회로
    • 의료 업계의 밝은 전망이 시장 성장을 유망하게
  • 주목해야 할 시장 동향 및 성장 촉진요인
  • 경쟁
    • 유세포분석기 시장
    • 전문 조직이 혈액분석기 시장을 독점
    • 소프트웨어 및 서비스 : 혈액분석기 부문의 새로운 경쟁 분야
  • 제품 개요
  • 제품 도입/출시
  • 최근의 업계 활동
  • 주요 기업
    • Abbott Laboratories
    • BD Biosciences
    • Beckman Coulter, Inc.
    • Bio-Rad Laboratories, Inc.
    • CellaVision AB
    • Dako Denmark A/S
    • eBioscience, Inc.
    • EMD Millipore
    • F. Hoffmann-La Roche Ltd.
    • Grifols, S.A
    • Horiba Ltd.
    • Mindray Medical International Limited
    • Ortho-Clinical Diagnostics, Inc.
    • QIAGEN N.V.
    • Siemens Healthcare
    • Sysmex Corporation
    • Thermo Fisher Scientific, Inc.
  • 세계 시장 전망

제3장 시장

  • 미국
  • 캐나다
  • 일본
  • 유럽
  • 아시아태평양 지역
  • 라틴아메리카
  • 기타

경쟁 구도

KSM 15.12.22

Abstract:

Demand for Cancer Screening Builds Up, Following Months of Delayed Care. Cell Surface Markers to Reach $1.1Billion

Global market for Cell Surface Markers is expected to reach US$1.1 billion by the year 2027 trailing a post pandemic growth rate of 8.9% for the period 2020 to 2027.Several health systems across the world have begun resuming non-COVID-19 care procedures. Demand is expected to spike in the coming months as delayed care leads to management of more critical cases. The impact of delayed care in oncology is especially expected to be severe with delayed diagnosis and lack of timely treatment likely to increase healthcare costs and mortality. The scenario is expected to create pent-up demand for cancer screening worldwide and spur demand for cell surface markers for cancer stem cells used in diagnostics & drug delivery. Both the United States and the U.K have witnessed over 65% reduction in breast cancer checks during Covid-19. Hospitals the world over will be faced with a huge backlog of cancer screening tests which has been accumulating during the Covid-19 pandemic to be cleared in the coming months. The scenario is a significant setback to the global fight against cancer. Missed diagnosis and delayed surgeries are expected to push up cancer mortality rates significantly over the next few years.

Cell surface markers or cell surface antigens are special carbohydrates or proteins present on cell membrane and can be exploited for identification and classification of cells. While certain proteins participate in transportation of molecules through the membrane, cell surface markers hold a pivotal role in intercellular recognition and communication. These surface markers act exclusive fingerprint of a cell and can be used in a diverse spectrum of applications. Cell surface markers are finding increasing use in research, disease diagnosis, drug discovery, personalized medicine and direct treatment for a specific medical condition. These markers allow researchers to determine cell expression of specific receptors to gain insights into biological response. Cell surface markers are commonly used to evaluate cell proliferation and abnormal cell population along with assessment and quantification of residual diseases. The increasing focus on timely diagnosis for disease prevention and reducing burden on healthcare system is driving the demand for cell surface markers. Over the years, application of cell surface markers has expanded beyond lymphocytes to detection of monocytes, macrophages, progenitor cells, and tumor cells. Cell surface markers exhibit the potential to revolutionize stem cell research. Other exciting areas include personalized medicine wherein analysis and understanding of cells isolated from patients and their response to specific therapy would allow the physician to make safer and effective medical decisions. Further, the introduction of monoclonal antibody producing hybridoma technology is further expanding the application options for cell surface markers. A growing number of healthcare facilities including hospitals, doctor`s offices, and diagnostic centers, as well as research entities including pharmaceutical laboratories, independent research institutions, academic/university research programs, and contract research organizations are prioritizing cell surface markers identification in diagnosis as well as research applications.

An interesting new application area is the growing focus of the researcher community to identify cell surface markers associated with COVID-19 to aid in diagnosis. Researchers have noted variations in immunological state, particularly changes in the normal ratio between CD4 and CD8 ratio in viral infections owing to antiviral immune responses. The normal CD4:CD8 ratio, 2:1, is inverted to less than 1:1 in certain viral infections, which can be used as diagnostic marker. In a recent effort in this direction, researchers used flow cytometry to determine the number of CD4 T and CD8 T cells in blood specimens of COVID-19 patients for finding the CD4:CD8 ratio. Researchers also determined the mean fluorescence intensity (MFI) of cellular markers for identifying their expression. The close resemblance of symptoms of common cold with initial signs of COVID-19 is prompting various hospitals to consider C-reactive protein (CRP) reagents to differentiate the two conditions. CRP is a primary cell marker that can assist physicians in diagnosing and follow-up treatment for the novel coronavirus (2019-nCoV). Patients with fever and a number of other suspected symptoms undergo CRP along with whole blood cell count testing to help clinicians in identifying common cold from COVID-19 infection. Physicians also conduct nucleic acid test and chest imaging to confirm patients with COVID-19. In addition, clinicians monitor CRP and other biochemical markers during the treatment through to patient recovery.

Select Competitors (Total 70 Featured) -

  • Abbott Laboratories, Inc.
  • BD Biosciences
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols, S.A.
  • Immucor, Inc.
  • Nihon Kohden Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Cell Surface Markers: A Prelude
    • Researchers Identify Over-Expression of CD8 Marker on Cytotoxic T-Cells in Patients with COVID-19 Infection
    • Hospitals Eye on CRP as Diagnostic Marker to Distinguish Common Cold from COVID-19
    • Robust Demand for Analytical Techniques and Focus on Timely Diagnosis Drive Growth of Global Cell Surface Markers Market
    • Research Dominates Cell Surface Markers Market, Clinical Diagnostics to Exhibit Fastest Growth
    • Flow Cytometers Lead the Cell Surface Markers Market
    • T and B Cells Dominate the Market
    • Developed Regions: Major Revenue Contributors
    • Developing Regions Drive Future Growth
  • 2. FOCUS ON SELECT PLAYERS
    • Recent Market Activity
    • Innovations & Advancements
  • 3. MARKET TRENDS & DRIVERS
    • High Uptake in Drug Discovery Applications Widens Market Prospects
    • Role of Flow Cytometry in Cell Line Development
    • Multicolor Flow Cytometry Offers Perfect Option to Understand B-Cell Development
    • Hematology Analyzers Gain Traction in Cell Surface Marker Identification
    • Growing Hematology Analyzers Market Witnesses Steady Growth
    • Key Technology Trends in Hematology Analyzers Market
    • Rising Cancer Incidence Worldwide Spurs Demand For Cell Surface Markers
    • Select Markers for Cancer Stem Cell Identification
    • EXHIBIT 1: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • EXHIBIT 2: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
    • EXHIBIT 3: Number of New Cancer Cases and Deaths (in Million) by Region for 2018
    • Use of CD Markers in Identification and Classification of Leukocyte Populations
    • Most Common CD markers for Flow Cytometry
    • Growing Significance of Personalized Medicine: An Opportunity for Cell Surface Markers
    • EXHIBIT 4: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019 and 2024
    • RNA Sequencing Emerges as Potential Approach to Identify Cell Surface Markers for Enabling Precision Medicine
    • Cell Surface Markers Grow Significantly in Stem Cell Research
    • Select Cell Surface Markers Used in Stem Cell Identification and Characterization
    • Hematopoietic Stem Cell Markers Provide Useful Insights into Hematopoiesis
    • Genetically Engineered CAR T-Cells Present Potential Weapon to Eliminate Cancer Stem Cells and Prevent Recurrence of Cancer
    • Key Models
    • CSC Population & Noteworthy Markers
    • ALDH
    • CD44
    • CD90
    • CD133
    • EpCAM & EGFR
    • Immunotherapy Targets Natural Killer Cells to Offer Hope for Cancer Patients
    • Cell Surface Markers Identification Assumes Critical Importance amid Growing Prevalence of Chronic Diseases
    • EXHIBIT 5: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • EXHIBIT 6: Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • Aging Demographics Present Opportunities for Cell Surface Markers
    • EXHIBIT 7: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
    • Clinical Management of Autoimmune Diseases
    • Flow Cytometry Remains the Gold Standard in HIV Testing and Monitoring
    • EXHIBIT 8: Global HIV Prevalence: 2019
    • Increased Emphasis on Lab Automation Builds Opportunities
    • Increasing Investments on Advanced Equipment in Disease Diagnosis Underpin Volume Growth
    • Growing Focus on Data Management in Research Programs Extends Opportunities
    • Rat Markers
    • Lineage and Antibodies Specific Rat Markers
    • Commonly Used Key Rat Markers by Antibodies and Research Area/Target Cell
    • New Anti-Rat Antibodies Products Expand Scope of Applications
    • ED Clone Anti-Rat Antibodies by Marker and Cell Type
    • Rat Flow Cytometry Panels
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Cell Surface Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 2: World Historic Review for Cell Surface Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 3: World 15-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 5: World Historic Review for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 6: World 15-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for PCR Arrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 8: World Historic Review for PCR Arrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 9: World 15-Year Perspective for PCR Arrays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for T Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 11: World Historic Review for T Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 12: World 15-Year Perspective for T Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for B Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 14: World Historic Review for B Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 15: World 15-Year Perspective for B Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for NK Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 17: World Historic Review for NK Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 18: World 15-Year Perspective for NK Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Monocyte Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 20: World Historic Review for Monocyte Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 21: World 15-Year Perspective for Monocyte Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 23: World Historic Review for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 24: World 15-Year Perspective for Other Cell Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 26: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 27: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 29: World Historic Review for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 30: World 15-Year Perspective for Clinical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 32: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 33: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Hospitals & Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 35: World Historic Review for Hospitals & Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 36: World 15-Year Perspective for Hospitals & Clinical Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 38: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 39: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

    • GEOGRAPHIC MARKET ANALYSIS
    • UNITED STATES
    • Largest Market for Cell Surface Markers
    • Rising Cancer Cases Spur Growth in Cell Surface Markers Market
    • EXHIBIT 9: Estimated Number of New Cancer Cases and Deaths in the US (2019)
    • EXHIBIT 10: Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
    • Market Benefits from Growing Funding for Stem Cell Research
    • EXHIBIT 11: Stem Cell Research Funding in the US (in US$ Million) for the Years 2011 through 2017
    • Market Analytics
    • TABLE 40: USA Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 41: USA Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 42: USA 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 43: USA Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 44: USA Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 45: USA 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 46: USA Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 47: USA Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 48: USA 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 49: USA Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 50: USA Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 51: USA 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • CANADA
    • High Focus on Improving Healthcare Augurs Well for Market Growth
    • EXHIBIT 12: Number of New Cancer Cases in Canada: 2019
    • Market Analytics
    • TABLE 52: Canada Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 53: Canada Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 54: Canada 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 55: Canada Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 56: Canada Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 57: Canada 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 58: Canada Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 59: Canada Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 60: Canada 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 61: Canada Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 62: Canada Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 63: Canada 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • JAPAN
    • TABLE 64: Japan Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 65: Japan Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 66: Japan 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 67: Japan Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 68: Japan Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 69: Japan 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 70: Japan Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 71: Japan Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 72: Japan 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 73: Japan Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 74: Japan Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 75: Japan 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • CHINA
    • Increasing Cancer Research to Drive Cell Surface Markers Market
    • EXHIBIT 13: Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
    • Market Analytics
    • TABLE 76: China Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 77: China Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 78: China 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 79: China Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 80: China Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 81: China 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 82: China Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 83: China Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 84: China 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 85: China Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 86: China Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 87: China 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • EUROPE
    • Market Facts & Figures
    • EXHIBIT 14: Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
    • Market Analytics
    • TABLE 88: Europe Current & Future Analysis for Cell Surface Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 89: Europe Historic Review for Cell Surface Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 90: Europe 15-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 91: Europe Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 92: Europe Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 93: Europe 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 94: Europe Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 95: Europe Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 96: Europe 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 97: Europe Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 98: Europe Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 99: Europe 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 100: Europe Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 101: Europe Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 102: Europe 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • FRANCE
    • TABLE 103: France Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 104: France Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 105: France 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 106: France Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 107: France Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 108: France 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 109: France Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 110: France Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 111: France 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 112: France Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 113: France Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 114: France 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • GERMANY
    • TABLE 115: Germany Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 116: Germany Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 117: Germany 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 118: Germany Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 119: Germany Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 120: Germany 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 121: Germany Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 122: Germany Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 123: Germany 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 124: Germany Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 125: Germany Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 126: Germany 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • ITALY
    • TABLE 127: Italy Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 128: Italy Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 129: Italy 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 130: Italy Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 131: Italy Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 132: Italy 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 133: Italy Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 134: Italy Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 135: Italy 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 136: Italy Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 137: Italy Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 138: Italy 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • UNITED KINGDOM
    • TABLE 139: UK Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 140: UK Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 141: UK 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 142: UK Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 143: UK Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 144: UK 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 145: UK Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 146: UK Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 147: UK 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 148: UK Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 149: UK Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 150: UK 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • SPAIN
    • TABLE 151: Spain Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 152: Spain Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 153: Spain 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 154: Spain Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 155: Spain Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 156: Spain 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 157: Spain Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 158: Spain Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 159: Spain 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 160: Spain Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 161: Spain Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 162: Spain 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • RUSSIA
    • TABLE 163: Russia Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 164: Russia Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 165: Russia 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 166: Russia Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 167: Russia Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 168: Russia 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 169: Russia Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 170: Russia Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 171: Russia 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 172: Russia Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 173: Russia Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 174: Russia 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • REST OF EUROPE
    • TABLE 175: Rest of Europe Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 176: Rest of Europe Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 177: Rest of Europe 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 178: Rest of Europe Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 179: Rest of Europe Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 180: Rest of Europe 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 181: Rest of Europe Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 182: Rest of Europe Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 183: Rest of Europe 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 184: Rest of Europe Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 185: Rest of Europe Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 186: Rest of Europe 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • ASIA-PACIFIC
    • Increased Cancer Research to Drive the Market for Cell Surface Markers
    • EXHIBIT 15: Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
    • Market Analytics
    • TABLE 187: Asia-Pacific Current & Future Analysis for Cell Surface Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 188: Asia-Pacific Historic Review for Cell Surface Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 189: Asia-Pacific 15-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 190: Asia-Pacific Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 191: Asia-Pacific Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 192: Asia-Pacific 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 193: Asia-Pacific Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 194: Asia-Pacific Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 195: Asia-Pacific 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 196: Asia-Pacific Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 197: Asia-Pacific Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 198: Asia-Pacific 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 199: Asia-Pacific Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 200: Asia-Pacific Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 201: Asia-Pacific 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • AUSTRALIA
    • TABLE 202: Australia Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 203: Australia Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 204: Australia 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 205: Australia Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 206: Australia Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 207: Australia 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 208: Australia Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 209: Australia Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 210: Australia 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 211: Australia Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 212: Australia Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 213: Australia 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • INDIA
    • TABLE 214: India Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 215: India Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 216: India 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 217: India Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 218: India Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 219: India 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 220: India Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 221: India Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 222: India 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 223: India Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 224: India Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 225: India 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • SOUTH KOREA
    • TABLE 226: South Korea Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 227: South Korea Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 228: South Korea 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 229: South Korea Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 230: South Korea Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 231: South Korea 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 232: South Korea Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 233: South Korea Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 234: South Korea 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 235: South Korea Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 236: South Korea Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 237: South Korea 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • REST OF ASIA-PACIFIC
    • TABLE 238: Rest of Asia-Pacific Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 239: Rest of Asia-Pacific Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 240: Rest of Asia-Pacific 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 241: Rest of Asia-Pacific Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 242: Rest of Asia-Pacific Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 243: Rest of Asia-Pacific 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 244: Rest of Asia-Pacific Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 245: Rest of Asia-Pacific Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 246: Rest of Asia-Pacific 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 247: Rest of Asia-Pacific Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 248: Rest of Asia-Pacific Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 249: Rest of Asia-Pacific 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • LATIN AMERICA
    • TABLE 250: Latin America Current & Future Analysis for Cell Surface Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 251: Latin America Historic Review for Cell Surface Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 252: Latin America 15-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 253: Latin America Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 254: Latin America Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 255: Latin America 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 256: Latin America Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 257: Latin America Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 258: Latin America 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 259: Latin America Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 260: Latin America Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 261: Latin America 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 262: Latin America Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 263: Latin America Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 264: Latin America 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • ARGENTINA
    • TABLE 265: Argentina Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 266: Argentina Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 267: Argentina 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 268: Argentina Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 269: Argentina Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 270: Argentina 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 271: Argentina Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 272: Argentina Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 273: Argentina 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 274: Argentina Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 275: Argentina Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 276: Argentina 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • BRAZIL
    • TABLE 277: Brazil Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 278: Brazil Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 279: Brazil 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 280: Brazil Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 281: Brazil Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 282: Brazil 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 283: Brazil Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 284: Brazil Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 285: Brazil 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 286: Brazil Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 287: Brazil Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 288: Brazil 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • MEXICO
    • TABLE 289: Mexico Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 290: Mexico Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 291: Mexico 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 292: Mexico Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 293: Mexico Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 294: Mexico 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 295: Mexico Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 296: Mexico Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 297: Mexico 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 298: Mexico Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 299: Mexico Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 300: Mexico 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • REST OF LATIN AMERICA
    • TABLE 301: Rest of Latin America Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 302: Rest of Latin America Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 303: Rest of Latin America 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 304: Rest of Latin America Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 305: Rest of Latin America Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 306: Rest of Latin America 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 307: Rest of Latin America Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 308: Rest of Latin America Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 309: Rest of Latin America 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 310: Rest of Latin America Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 311: Rest of Latin America Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 312: Rest of Latin America 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • MIDDLE EAST
    • TABLE 313: Middle East Current & Future Analysis for Cell Surface Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 314: Middle East Historic Review for Cell Surface Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 315: Middle East 15-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 316: Middle East Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 317: Middle East Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 318: Middle East 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 319: Middle East Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 320: Middle East Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 321: Middle East 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 322: Middle East Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 323: Middle East Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 324: Middle East 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 325: Middle East Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 326: Middle East Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 327: Middle East 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • IRAN
    • TABLE 328: Iran Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 329: Iran Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 330: Iran 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 331: Iran Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 332: Iran Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 333: Iran 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 334: Iran Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 335: Iran Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 336: Iran 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 337: Iran Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 338: Iran Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 339: Iran 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • ISRAEL
    • TABLE 340: Israel Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 341: Israel Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 342: Israel 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 343: Israel Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 344: Israel Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 345: Israel 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 346: Israel Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 347: Israel Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 348: Israel 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 349: Israel Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 350: Israel Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 351: Israel 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • SAUDI ARABIA
    • TABLE 352: Saudi Arabia Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 353: Saudi Arabia Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 354: Saudi Arabia 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 355: Saudi Arabia Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 356: Saudi Arabia Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 357: Saudi Arabia 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 358: Saudi Arabia Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 359: Saudi Arabia Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 360: Saudi Arabia 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 361: Saudi Arabia Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 362: Saudi Arabia Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 363: Saudi Arabia 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • UNITED ARAB EMIRATES
    • TABLE 364: UAE Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 365: UAE Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 366: UAE 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 367: UAE Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 368: UAE Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 369: UAE 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 370: UAE Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 371: UAE Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 372: UAE 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 373: UAE Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 374: UAE Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 375: UAE 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • REST OF MIDDLE EAST
    • TABLE 376: Rest of Middle East Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 377: Rest of Middle East Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 378: Rest of Middle East 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 379: Rest of Middle East Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 380: Rest of Middle East Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 381: Rest of Middle East 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 382: Rest of Middle East Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 383: Rest of Middle East Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 384: Rest of Middle East 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 385: Rest of Middle East Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 386: Rest of Middle East Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 387: Rest of Middle East 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
    • AFRICA
    • TABLE 388: Africa Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 389: Africa Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 390: Africa 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2020 & 2027
    • TABLE 391: Africa Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 392: Africa Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 393: Africa 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2020 & 2027
    • TABLE 394: Africa Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 395: Africa Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 396: Africa 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2020 & 2027
    • TABLE 397: Africa Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 398: Africa Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
    • TABLE 399: Africa 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2020

IV. COMPETITION

  • Total Companies Profiled: 187
Back to Top
전화 문의
F A Q